You appear to be using an older version of Internet Explorer. We suggest you upgrade your browser for the best viewing experience. Upgrade to a Modern Browser
26 January 2022
欧州でも日本と同様に審査・異議申立で追加実験データが多用されます。欧州では進歩性の判断における検討事項が多いこと、異議申立の件数が日本の無効審判と比べて10倍近くあることから、日本よりも実験データを提出することは多いように思えます。 今回は実験データを用いて拒絶理由・異議理由を克服するためのストラテジー及び実験データを用いて異議理由を補強する方法について練習問題を交えながら解説致します。 欧州特許を既に経験されている日本の実務家に向けて少し踏み込んだ内容を５０分程度で解説し、その後質疑応答の時間を用意します。講義資料は日本語です。欧州弁理士が解説を担当する部分は日本語字幕が付きます。質疑応答も日本語で対応します。 無料ウェビナーで特に人数制限もございませんのでご同僚の方々もお誘いのうえご視聴下さい。 クリックしてご登録下さい。
7 - 11 February 2022
Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings. Biotechgate Digital Partnering is designed to support the business development of Biotech, Medtech and Pharma companies. J A Kemp Associate, Feng Rao will be attending this virtual event.
17 February 2022
J A Kemp partner, Amanda Simons will be speaking at this OBN event, sharing her expert insight on the opportunities available to companies who are seeking ways to maximise their product's assets during early development. The session will provide a comprehensive strategic focus on up-to-date regulatory and IP matters including: Regulatory Strategy Engaging with regulators early in development to enhance probability of regulatory success. Incentives offering short term financial gains and long term impact e.g. orphan drug designation; EMA's PRIME scheme and UK's Innovative Licensing and Access Pathway (ILAP including the Innovation Passport) for priority medicines; the UK's Early Access to Medicines Scheme (EAMS) including...
22 February 2022
The law on plausibility continues to be a hot topic in the pharmaceutical and biotech fields. This webinar will cover recent developments in the assessment of whether a “plausible” disclosure of efficacy is present in the application as filed. This will include discussion of the decision T 116/18 which has for the first time referred the topic of plausibility to the Enlarged Board of Appeal of the European Patent Office (pending as G 2/21). The Court of Appeal decision in Fibrogen v Akebia will also be covered, which discusses the issue of plausibility in the context of claims directed to...
1 March 2022
The patent landscape in Europe is about to undergo the biggest change since the European Patent Office was established four decades ago. The introduction of the Unitary Patent and Unified Patent Court will affect all applicants and patentees seeking patent protection in Europe through the European Patent Office. The webinar will explain the changes and set out a timetable for decisions which patentees, applicants and their attorneys will need to make. Careful consideration will need to be given in the coming months on existing granted European patents and pending applications at the EPO as they approach grant and following grant. Topics...
26 - 27 April 2022
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. The event is attended by an ever-evolving audience of early stage and emerging life sciences R&D Companies, investors, large pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions. BioTrinity will take place online and in-person. J A Kemp Partner, Amanda Simons and Associate, Karen Ng will be attending in-person this year.